1,061
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Amgen's recently active trials. Comparator arms are excluded.
- Tarlatamab9 trials
- Rocatinlimab9 trials
- Maridebart Cafraglutide7 trials
- Maridebart cafraglutide6 trials
- Xaluritamig6 trials
- Blinatumomab6 trials
Upcoming readouts
Next primary completion dates among Amgen's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Jun 2027A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet …Phase 3
- Jun 2027A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodi…Phase 3
- Jul 2027A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Afl…Phase 3
- Sept 2027DeLLphi-315: Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum …Phase 3
- Sept 2027MARITIME-OSA-2: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on…Phase 3
- Sept 2027MARITIME-OSA-1: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Pos…Phase 3
Top therapeutic areas
Conditions studied most often across Amgen's recently active trials.
- Obesity7 trials
- Atopic Dermatitis7 trials
- Overweight5 trials
- Extensive Stage Small Cell Lung Cancer4 trials
- Thyroid Eye Disease4 trials
- Prostate Cancer3 trials
Amgen pipeline by phase
The main study drugs across 97 active trials Amgen leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 320 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Maridebart Cafraglutide | 14 | 8 | Nov 2026 est. | NCT07684235 · NCT07684144 · NCT07575399 |
| Tarlatamab | 12 | 3 | Dec 2026 est. | NCT07778316 · NCT07005128 · NCT06211036 |
| XaluritamigAMG 509 | 8 | 6 | Feb 2027 est. | NCT07213674 · NCT06691984 · NCT07493512 |
| Blinatumomab | 5 | — | Nov 2027 est. | NCT07223190 · NCT04994717 · NCT06054113 |
| Apremilast | 4 | 3 | Mar 2028 est. | NCT05767047 · NCT05565560 · NCT04804553 |
| Olpasiran | 3 | 2 | Mar 2028 est. | NCT07293260 · NCT07136012 · NCT05581303 |
| Sotorasib | 3 | 2 | Dec 2026 est. | NCT05920356 · NCT07172919 · NCT04185883 |
| ABP 234 | 2 | — | Dec 2026 est. | NCT06430866 · NCT06311721 |
| Dazodalibep | 2 | 1 | Oct 2026 est. | NCT06747949 · NCT06245408 |
| Etelcalcetide | 2 | 2 | Jun 2027 est. | NCT03969329 · NCT03633708 |
| Romiplostim | 2 | — | Sept 2029 est. | NCT07700238 · NCT03937154 |
| Romosozumab | 2 | — | Jan 2027 est. | NCT05972551 · NCT07811999 |
| ABP 206 | 1 | — | Jan 2028 est. | NCT06054555 |
| ABP 692 | 1 | — | Apr 2027 est. | NCT06700343 |
| ABP 938 8 mg | 1 | 1 | Jul 2027 est. | NCT07614776 |
| Erenumab Dose 1 | 1 | — | — | NCT03836040 |
| FOLFIRI Regimen | 1 | 1 | Sept 2028 est. | NCT06252649 |
| Pegloticase | 1 | 1 | Jun 2028 est. | NCT07388498 |
| Teprotumumab | 1 | — | — | NCT06248619 |
| Vitamin D | 1 | 1 | Apr 2028 est. | NCT07366086 |
Phase 22 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Anvumetostat | 4 | — | Oct 2026 est. | NCT06593522 · NCT06360354 · NCT06333951 |
| AMG 732 | 2 | 1 | Jan 2027 est. | NCT07438405 · NCT06401044 |
Phase 19 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| AMG 691 | 2 | 1 | Mar 2027 est. | NCT07745907 · NCT06637371 |
| AMG 127 | 1 | 1 | Oct 2027 est. | NCT07590193 |
| AMG 410 | 1 | 1 | Apr 2028 est. | NCT07094113 |
| AMG 436 | 1 | 1 | Jul 2028 est. | NCT07403721 |
| AMG 513 | 1 | — | Sept 2026 est. | NCT06585462 |
| COC | 1 | — | Nov 2026 est. | NCT07523711 |
| Evolocumab Drug Substance A (Test) | 1 | — | — | NCT07545226 |
| YL201 | 1 | — | Jun 2031 est. | NCT06898957 |
| ZL-1310 | 1 | 1 | May 2028 est. | NCT07531095 |
Phase 46 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Inebilizumab | 8 | 3 | Apr 2027 est. | NCT06180278 · NCT07598825 · NCT04540497 |
| Avacopan | 2 | 1 | Jul 2027 est. | NCT06072482 · NCT06321601 |
| Evolocumab | 1 | — | May 2027 est. | NCT05284747 |
| Prolia | 1 | — | Jan 2027 est. | NCT06332014 |
| Prolia® | 1 | — | Apr 2027 est. | NCT06588153 |
| XGEVA® | 1 | — | Mar 2028 est. | NCT04586660 |
Derived from 97 active trials Amgen leads; 97 name an intervention, folding into 37 phased drugs. This is ComplyRx's reading of the registry, not Amgen's own pipeline disclosure.
Amgen trials
The 50 most significant of Amgen's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Single and Multiple Ascending Dose Study of AMG 513 in Participants With ObesityNCT06585462AMG 513 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 82 est. | 24 Sept 2026 |
| MTAPESTRY 103A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)NCT06360354Anvumetostat | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 120 est. | 31 Oct 2026 |
| A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257Maridebart cafraglutide | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 56 est. | 15 Nov 2026 |
| Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711COC | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 49 est. | 18 Nov 2026 |
| MTAPESTRY 101A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)NCT05094336Anvumetostat | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 329 est. | 30 Nov 2026 |
| A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseNCT06401044AMG 732 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 94 est. | 6 Jan 2027 |
| Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC InjectionsNCT07811999Romosozumab | Phase 1 | Not yet scored | OngoingNot yet recruiting | 308 est. | 14 Jan 2027 |
| Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerNCT06613100Xaluritamig | Phase 1 | Locked · track to reveal | OngoingRecruiting | 40 est. | 17 Feb 2027 |
| Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerNCT06555796Xaluritamig | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 50 est. | 13 Mar 2027 |
| A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese VolunteersNCT07745907AMG 691 | Phase 1 | Not yet scored | OngoingRecruiting | 28 est. | 31 Mar 2027 |
| A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate AsthmaNCT06637371AMG 691 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 21 est. | 10 Apr 2027 |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)NCT06700343Ocrelizumab (US) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 152 est. | 19 Apr 2027 |
| DeLLphi-308Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)NCT06598306Tarlatamab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 220 est. | 24 Apr 2027 |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356Sotorasib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 750 est. | 30 Jun 2027 |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving HemodialysisNCT03969329Etelcalcetide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 24 est. | 30 Jun 2027 |
| Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.NCT06321601Avacopan | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 19 est. | 18 Jul 2027 |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationNCT07614776ABP 938 8 mg | Phase 3 | Locked · track to reveal | OngoingRecruiting | 304 est. | 31 Jul 2027 |
| DeLLphi-315Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)NCT07778316Tarlatamab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 400 est. | 24 Sept 2027 |
| MARITIME-OSA-2Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765Maridebart cafraglutide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 250 est. | 29 Sept 2027 |
| MARITIME-OSA-1Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686Maridebart cafraglutide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 250 est. | 29 Sept 2027 |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252Maridebart cafraglutide | Phase 2 | Locked · track to reveal | OngoingRecruiting | 180 est. | 29 Sept 2027 |
| A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes MellitusNCT07590193AMG 127 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 162 est. | 2 Oct 2027 |
| A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLNCT04521231Blinatumomab | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 181 est. | 24 Nov 2027 |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NCT07684144Maridebart Cafraglutide | Phase 3 | Not yet scored | OngoingRecruiting | 950 est. | 26 Dec 2027 |
| Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235Maridebart cafraglutide | Phase 3 | Not yet scored | OngoingRecruiting | 3,200 est. | 26 Dec 2027 |
| DeLLphi-301A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)NCT05060016Tarlatamab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 222 est. | 30 Dec 2027 |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399Maridebart Cafraglutide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 300 est. | 3 Jan 2028 |
| HAZEL 401An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye DiseaseNCT07438405AMG 732 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 30 est. | 29 Jan 2028 |
| DeLLphi-311A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)NCT07037758Tarlatamab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 380 est. | 18 Mar 2028 |
| PEAPODApremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisNCT04804553Apremilast | Phase 3 | Locked · track to reveal | OngoingRecruiting | 60 est. | 21 Mar 2028 |
| Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerNCT07140900Xaluritamig | Phase 1 | Locked · track to reveal | OngoingRecruiting | 60 est. | 27 Mar 2028 |
| AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsNCT07094113AMG 410 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 434 est. | 18 Apr 2028 |
| Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaNCT07366086Vitamin D | Phase 3 | Locked · track to reveal | OngoingRecruiting | 71 est. | 19 Apr 2028 |
| DeLLphi-313Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)NCT07531095ZL-1310 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 160 est. | 21 May 2028 |
| A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled GoutNCT07388498Pegloticase | Phase 3 | Locked · track to reveal | OngoingRecruiting | 270 est. | 18 Jun 2028 |
| MARITIME-HFMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459Maridebart cafraglutide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 5,056 est. | 30 Jun 2028 |
| MARITIME-CVEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433Maridebart Cafraglutide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 12,800 est. | 30 Jun 2028 |
| A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationNCT07172919Sotorasib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 14 est. | 1 Jul 2028 |
| AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid TumorsNCT07403721AMG 436 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 464 est. | 28 Jul 2028 |
| A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesNCT06570798Inebilizumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 220 est. | 6 Aug 2028 |
| CodeBreaK 301Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationNCT06252649FOLFIRI Regimen | Phase 3 | Locked · track to reveal | OngoingRecruiting | 450 est. | 25 Sept 2028 |
| A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular DiseaseNCT06295679 | — | Not yet scored | OngoingActive, not recruiting | 7,000 est. | 19 Dec 2028 |
| DeLLphi-312A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128Tarlatamab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 350 est. | 4 Jan 2029 |
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical AtheromaNCT07803679Evolocumab | Phase 4 | Not yet scored | OngoingNot yet recruiting | 308 est. | 30 Apr 2029 |
| DeLLphi-309A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCNCT06745323Tarlatamab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 252 est. | 10 May 2029 |
| Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic LeukemiaNCT04994717Blinatumomab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 303 est. | 7 Sept 2029 |
| ROMISTERA Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)NCT07700238Romiplostim | Phase 3 | Not yet scored | OngoingNot yet recruiting | 126 est. | 14 Sept 2029 |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674Xaluritamig | Phase 3 | Locked · track to reveal | OngoingRecruiting | 750 est. | 7 Jan 2030 |
| BEANApremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's DiseaseNCT04528082Apremilast | Phase 3 | Locked · track to reveal | OngoingRecruiting | 60 est. | 7 Feb 2030 |
| THYMEA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)NCT06987539Inebilizumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 15 est. | 13 Mar 2030 |